Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412 (2014)
- Authors:
- Campos, Paula de Melo - Universidade Estadual de Campinas (UNICAMP)
- Machado Neto, João Agostinho - Universidade Estadual de Campinas (UNICAMP)
- Scopim-Ribeiro, Renata - Universidade Estadual de Campinas (UNICAMP)
- Visconte, Valeria
- Tabarroki, Ali
- Duarte, Adriana S. S - Universidade Estadual de Campinas (UNICAMP)
- Barra, Flávia F. C - Universidade Estadual de Campinas (UNICAMP)
- Vassalo, José - Universidade Estadual de Campinas (UNICAMP)
- Rogers, Heesun J
- Lorand-Metze, Irene - Universidade Estadual de Campinas (UNICAMP)
- Tiu, Ramon V
- Costa, Fernando F - Universidade Estadual de Campinas (UNICAMP)
- Saad, Sara T. Olalla - Universidade Estadual de Campinas (UNICAMP)
- Traina, Fabiola
- Autor USP: TRAINA, FABÍOLA - FMRP
- Unidade: FMRP
- DOI: 10.1016/j.leukres.2014.07.010
- Subjects: APOPTOSE (EFEITOS DE DROGAS); PROTEÍNAS PROTO-ONCOGÊNICAS; PROTEÍNAS QUINASES
- Language: Inglês
- Imprenta:
- Publisher place: Kidlington
- Date published: 2014
- Source:
- Título: Leukemia Research
- ISSN: 0145-2126
- Volume/Número/Paginação/Ano: v. 38, n. 10, p. 1245-1251, 2014
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
CAMPOS, Paula de Melo et al. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia Research, v. 38, n. 10, p. 1245-1251, 2014Tradução . . Disponível em: https://doi.org/10.1016/j.leukres.2014.07.010. Acesso em: 26 jan. 2026. -
APA
Campos, P. de M., Machado Neto, J. A., Scopim-Ribeiro, R., Visconte, V., Tabarroki, A., Duarte, A. S. S., et al. (2014). Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia Research, 38( 10), 1245-1251. doi:10.1016/j.leukres.2014.07.010 -
NLM
Campos P de M, Machado Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte ASS, Barra FFC, Vassalo J, Rogers HJ, Lorand-Metze I, Tiu RV, Costa FF, Saad STO, Traina F. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412 [Internet]. Leukemia Research. 2014 ; 38( 10): 1245-1251.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1016/j.leukres.2014.07.010 -
Vancouver
Campos P de M, Machado Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte ASS, Barra FFC, Vassalo J, Rogers HJ, Lorand-Metze I, Tiu RV, Costa FF, Saad STO, Traina F. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412 [Internet]. Leukemia Research. 2014 ; 38( 10): 1245-1251.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1016/j.leukres.2014.07.010 - Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia
- IL32 expression in peripheral blood CD3+ cells from myelodysplastic syndromes patients
- Hedgehog pathway is deregulated in myelodysplastic syndrome progenitor bone marrow cells
- Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome
- STMN1 (stathmin 1)
- Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms
- Differential profile of PIP4K2A expression in hematological malignancies
- FMNL1 is downregulated in myelodysplastic syndromes and is involved in megakaryocytic differentiation
- Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
- MDR-1 and GST polymorphisms are involved in myelodysplasia progression
Informações sobre o DOI: 10.1016/j.leukres.2014.07.010 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
